Application Notes:
Anti-ganglioside GD2 (anti-GD2) is very useful in the identification of disialoganglioside GD2 and in immunotargeting cells expressing disialoganglioside GD2. Several gangliosides have been found to have elevated expressions in tumor cells. Many therapeutic treatments of tumor cells are being investigated using antibodies to target cells that express these elevated levels of gangliosides. Disialoganglioside GD2 has been identified as a tumor-associated antigen and therapeutic approaches using anti-GD2 are being investigated and show great potential.1 Although many challenges must still be overcome in using this therapeutic approach progress is steadily going forward.2
Selected References:
1. M. Ozkaynak et al. “Phase I Study of Chimeric Human/Murine Anti–Ganglioside GD2 Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children’s Cancer Group Study” Journal of Clinical Oncology, Vol 18(24) pp. 4077-4085, 2000
2. J. Hu et al. “Reducing Epitope Spread during Affinity Maturation of an Anti-Ganglioside GD2 Antibody” The Journal of Immunology, Vol. 186(4) pp. 1-8, 2009